Sanofi Says Pfizer’s PCSK9 Phase III Plan Will Boost The New Drug Class
Sanofi CEO Christopher Viehbacher seemed unperturbed by Pfizer’s ambitious PCSK9 Phase III development program, saying it will increase interest in the new drug class.
Sanofi CEO Christopher Viehbacher seemed unperturbed by Pfizer’s ambitious PCSK9 Phase III development program, saying it will increase interest in the new drug class.